Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07889492) titled 'A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo' on Oct. 16.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Edesa Biotech Inc.
Condition:
Non-Segmental Vitiligo (NSV)
Intervention:
Other: Placebo IV
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: September 2026
Target Sample Size: 80
Countries of Recruitment:
Canad...